Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic search methodology or meta-analysis
PubMed 27703368 · doi:10.2147/JMDH.S106340
What was done
This narrative review summarizes the epidemiology, pathophysiology, and pharmacological pain management strategies for postherpetic neuralgia (PHN) following herpes zoster reactivation, highlighting first-line clinical guideline recommendations.
What was found
The abstract reports that approximately 1 million cases of herpes zoster occur annually in the United States, with a lifetime risk of one in three individuals. Postherpetic neuralgia arises from peripheral and central neuronal injury associated with inflammation during viral reactivation. Current clinical guidelines recommend a hierarchical treatment strategy using calcium channel alpha-2-delta ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line pharmacotherapies. No comparative efficacy data or numerical trial outcomes were reported in the abstract.
Why it matters
It provides a clinical overview of guideline-endorsed first-line therapies and emphasizes the importance of dose titration, adverse-effect monitoring, and patient education in older adults suffering from persistent post-shingles neuropathic pain.
Limits
The paper is a non-systematic narrative review providing broad clinical recommendations rather than new trial data or a quantitative meta-analysis. The abstract does not provide specific comparative risk-benefit statistics, study selection criteria, or sample size estimates.
Cited by
- supports Nerve pain during herpes virus reactivation is largely caused by the immune system reacting to the virus exiting neurons and killing off those neurons.